Conclusions and Future Research
Despite a recent, large RCT demonstrating no effect of L rhamnosus GG supplementation on acute gastroenteritis, current evidence shows that, overall, L rhamnosus GG reduced the durations of diarrhoea and hospitalisation of inpatients. These findings should be viewed in the context of the high heterogeneity and methodological limitations of the included trials. Nevertheless, these findings indicate that results of a recent, well-conducted RCT may not be sufficient to eliminate L rhamnosus GG from the treatment of children with acute gastroenteritis, at least in the European setting. The findings of this review may inform guideline development groups about the efficacy of L rhamnosus GG for treating children with acute gastroenteritis.
Acknowledgements
Declaration of personal interests
H. Szajewska has served as a speaker for companies manufacturing probiotics, including L rhamnosus GG. H. Szajewska is one of the investigators in a clinical trial on L rhamnosus GG included in this review. The remaining authors declare no conflict of interest.
Authorship
Guarantor of the article
Hania Szajewska.
Funding information
This study was funded in full by The Medical University of Warsaw.
Aliment Pharmacol Ther. 2019;49(11):1376-1384. © 2019 Blackwell Publishing
Comments